Get the Stockscreener App
250.49
2.82%
6.88
Overview
News
Price History
Option Chain
Financials
Why WST Down?
Discussions
Forecast
Stock Split
Dividend History
West Pharmaceutical Services Inc stock is traded at $250.49, with a volume of 978.09K.
It is up +2.82% in the last 24 hours and down -7.85% over the past month.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
See More
Previous Close:
$243.61
Open:
$243.94
24h Volume:
978.09K
Relative Volume:
1.14
Market Cap:
$18.02B
Revenue:
$2.96B
Net Income/Loss:
$487.70M
P/E Ratio:
37.52
EPS:
6.6758
Net Cash Flow:
$344.00M
1W Performance:
+0.62%
1M Performance:
-7.85%
6M Performance:
+1.73%
1Y Performance:
+25.80%
1-Day Range:
$242.14
$250.53
1-Week Range:
$227.49
$259.90
52-Week Range:
$187.43
$322.34
West Pharmaceutical Services Inc Stock (WST) Company Profile
Name
West Pharmaceutical Services Inc
Sector
Industry
Phone
(610) 594-2900
Address
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WST
West Pharmaceutical Services Inc
|
250.49 | 17.53B | 2.96B | 487.70M | 344.00M | 6.6758 |
|
ISRG
Intuitive Surgical Inc
|
485.84 | 169.97B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
175.89 | 50.58B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
79.20 | 38.58B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.55 | 37.11B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
252.55 | 35.80B | 5.40B | 1.49B | 1.78B | 10.12 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-15-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-24-25 | Initiated | Barclays | Equal Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-14-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-25 | Initiated | Citigroup | Buy |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-12-24 | Upgrade | UBS | Neutral → Buy |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-11-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Nov-30-22 | Initiated | UBS | Neutral |
| Oct-28-22 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-14-20 | Initiated | Stephens | Equal-Weight |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-24-20 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-12-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| May-01-19 | Downgrade | Jefferies | Buy → Hold |
| Apr-23-19 | Initiated | William Blair | Outperform |
| Apr-25-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-17-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-03-17 | Initiated | Stephens | Equal-Weight |
| Sep-15-17 | Upgrade | Jefferies | Hold → Buy |
| Oct-28-16 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Sep-21-16 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Mar-22-16 | Initiated | Wells Fargo | Outperform |
| May-14-10 | Reiterated | UBS | Neutral |
| Feb-23-10 | Initiated | Jefferies & Co | Buy |
| Dec-19-08 | Initiated | UBS | Neutral |
View All
West Pharmaceutical Services Inc Stock (WST) Latest News
Caprock Group LLC Purchases New Shares in West Pharmaceutical Services, Inc. $WST - MarketBeat
How sensitive is West Pharmaceutical Services Inc. to inflationJuly 2025 Catalysts & Consistent Profit Trade Alerts - mfd.ru
West Pharmaceutical Services (WST): Barclays Lowers Price Target - GuruFocus
Stephens Cuts Price Target on West Pharmaceutical Services to $320 From $350, Maintains Overweight Rating - marketscreener.com
West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2025 Earnings Call Transcript - Insider Monkey
West Pharmaceutical Services Q4 Earnings Call Highlights - Yahoo Finance
West Pharmaceutical targets 5%–7% organic revenue growth for 2026 as HVP demand accelerates - MSN
West Pharma forecasts 2026 profit above estimates on strong demand for drug components - 104.1 WIKY
Earnings call transcript: West Pharmaceutical Services Q4 2025 earnings beat expectations - Investing.com Canada
West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook - Yahoo Finance
West Pharmaceutical Q4 2025 slides: Revenue up 7.5%, EPS exceeds expectations - Investing.com Nigeria
West Pharmaceutical Services (NYSE:WST) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
West Pharmaceutical Services's (NYSE:WST) Q4 CY2025: Beats On Revenue, Stock Soars - Finviz
WST's Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up - Finviz
Iron Mountain Projects Double-Digit Growth in 2026 - Investing.com
West Pharmaceutical Q4 2025 slides: Revenue up 7.5%, EPS exceeds expectations By Investing.com - Investing.com India
West Pharmaceutical (WST) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
West Pharmaceutical Services (NYSE:WST) Issues FY 2026 Earnings Guidance - MarketBeat
West Pharmaceutical Q4 EPS Beats Estimates; Guides 2026 Sales Growth of 5% to 7% - AlphaStreet News
West Pharmaceutical (WST) Exceeds Market Expectations with Stron - GuruFocus
West Pharmaceutical Services, Inc. $WST Shares Sold by ING Groep NV - MarketBeat
West Pharma (WST) Q4 2025 Earnings Call Transcript - The Globe and Mail
West Pharmaceutical Services Posts Solid Q4 and 2025 Results - TipRanks
West Pharmaceutical (WST) Exceeds Revenue Expectations in Q4 - GuruFocus
West Pharmaceutical Services (WST) Projects FY26 Revenue Range - GuruFocus
Q4 Earnings Update: IRM, USFD, and WST Post Solid Q4 Results - Tokenist
Form 8-K WEST PHARMACEUTICAL SERV For: Feb 12 - StreetInsider
West Pharmaceutical Services (WST) Tops Q4 Earnings and Revenue Estimates - Yahoo! Finance Canada
West Pharmaceutical: Q4 Earnings Snapshot - kare11.com
West Pharmaceutical Servs Q4 Earnings Summary & Key Takeaways - Benzinga
WEST PHARMACEUTICAL SVSC ($WST) Releases Q4 2025 Earnings - Quiver Quantitative
West Pharma shares climb over 5% on strong fourth-quarter results - Investing.com UK
West Pharma shares climb over 5% on strong fourth-quarter results By Investing.com - Investing.com Nigeria
West Pharmaceutical: Q4 Financial Results Overview - Bitget
(WST) West Pharmaceutical Services, Inc. Expects Q1 Adjusted EPS Range $1.65$1.70 - marketscreener.com
West Pharmaceutical Services earnings beat by $0.20, revenue topped estimates - Investing.com Canada
West Pharmaceutical Services’s (NYSE:WST) Q4 CY2025: Beats On Revenue, Stock Soars - Yahoo Finance
(WST) West Pharmaceutical Expects 2026 Net Sales Range $3.22B to $3.28B, vs. FactSet Est of $3.24B - marketscreener.com
West Reports Fourth-Quarter and Full-Year 2025 Results – Company Announcement - Financial Times
Is West Pharmaceutical Services (NYSE:WST) a Pillar In S&P 500 Futures Performance - Kalkine Media
In the latest conference call, West Pharmaceutical Services Inc executives noted that although demand for GLP-1 drugs is showing strong growth momentum in 2025, the growth pace is expected to slow down in 2026. - Bitget
West Pharmaceutical faces earnings test as estimates drift lower By Investing.com - Investing.com Canada
Evaluating West Pharmaceutical Services (WST) Valuation As Earnings And GLP 1 Growth Stay In Focus - Sahm
West Pharmaceutical Services, Inc. (NYSE:WST) Receives Average Rating of "Buy" from Brokerages - MarketBeat
West Pharmaceutical Services Earnings Preview: Analysts Project $793.4M RevenueNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
West Pharmaceutical Services Earnings: What To Look For From WST - Finviz
West Pharmaceutical Services Inc (WST)'s Winning Formula: Financ - GuruFocus
Countdown to West Pharmaceutical (WST) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Jefferies Adjusts Price Target on West Pharmaceutical Services to $295 From $365, Maintains Buy Rating - marketscreener.com
Rockland Trust Co. Buys 5,087 Shares of West Pharmaceutical Services, Inc. $WST - MarketBeat
WST Q4 Earnings Preview: Can HVP Momentum Continue to Drive Margins? - TradingView
West Pharmaceutical Services Inc Stock (WST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):